Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
Key Highlights
- ➤Braveheart Bio will present BHB-1893 data at AHA Scientific Sessions 2026
- ➤52-week extension data for BHB-1893 in obstructive HCM gets late-breaking presentation
- ➤Oral presentation covers BHB-1893 diastolic-function findings in non-obstructive HCM
- ➤Presentations are scheduled for November 6, 2026, in Chicago
Expert Statements
Carlos del Rio, Senior Vice President, Cardiovascular Research & Translational Science, Braveheart Bio
“HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and Patients”
Xueyi Wu, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
“Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period”
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced two upcoming presentations, including a late-breaking presentation of 52-week extension data for BHB-1893 in obstructive HCM, at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, IL. Following the presentations, copies of the presentation materials will be available in the Investors section of the Braveheart Bio website.
Title: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and Patients Presenter: Carlos del Rio, Ph.D., Senior Vice President, Cardiovascular Research & Translational Science, Braveheart Bio Date: Friday, November 6, 2026 Session Title: Hypertrophic Cardiomyopathy Medical Society Abstract Oral Presentations Session Time: 9:45 AM – 10:45 AM CT Presentation Time: 10:15 AM – 10:25 AM CT Location: Room S406A, McCormick Place
Get started
Create a free account to read the full story.